Cookie Consent by Privacy Policies website

Elevai Biosciences is a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines.

Nearly half of Americans will have obesity by 2030

Currently, more than 40% of adults in the United States live with obesity — a figure predicted to rise to 50% by 2030. Obesity is a leading risk factor for the development of serious health conditions, including Type 2 diabetes and heart failure. Goldman Sachs predicts that this epidemic will create a $100 billion market for anti-obesity players

The Unmet Need With Blockbuster Obesity Drugs

Approved GLP-1 drugs used in weight loss, such as Novo Nordisk’s Ozempic® (semaglutide) & Wegovy®(semaglutide) and Eli Lilly’s Zepbound (tirzepatide), and Mounjaro® (tirzepatide) have transformed the obesity treatment landscape. However, past studies of these highly effective drugs show that up to 40% of the weight loss is due to loss of lean muscle.

Physicians have expressed concern around this problematic finding as muscle is necessary for metabolism, strength, and physical function. As a result, one of the key unmet needs in the current obesity landscape is the avoidance of muscle loss while on weight loss treatments.

Elevai is developing EL-22, an engineered probiotic with myostatin antigens, to elicit an immune response that could help people achieve substantial fat loss while preserving muscle mass.
Our Science

Our Team

Our team is comprised of passionate experts with decades of experience uncovering scientific insights, building innovative biotech companies, and bringing impactful clinical assets to market.

Management Team

Jordan R. Plews PhD, Chief Executive Officer

Graydon Bensler, CFA, Chief Financial Officer

Hatem Abou-Sayed, MD, MBA, FACS, Chief Medical Officer